Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
Key facts
- Who runs it
- General Hospital of Shenyang Military Region
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 22 people enrolled
- Started
- 28 Nov 2023
- Ended
- 30 Dec 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- umbilical cord-mesenchymal stem cells
- Record updated
- 3 April 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- 18-80 years old
- End-stage liver disease
- Sign informed consent
Who cannot take part
- Liver transplantation recipients
- Interferon or glucocorticoid therapy within 1 year
- Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
- Other diseases that may seriously affect the survival
- Human immunodeficiency syndrome
- Treated for mental illness
- Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
- Tumours of the liver or other organs
- Participation in other clinical trials within 30 days
- Pregnant or breastfeeding subjects
- Other circumstances that are unsuitable for participation in this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There is a rise in the prevalence of end-stage liver disease during the last decade. End-stage liver disease has become one of the leading causes of death in Western countries. Liver transplantation is the only curative treatment for patients with end-stage liver disease. However, the shortage of donor, high cost, and postoperative complications limit its wide application in clinical practice. At present, stem cell-based therapy has been developed as an alternative treatment for end-stage liver disease. Stem cells can be differentiated into a variety of cell types, and stem cell transplantation, mainly umbilical cord-mesenchymal stem cells, has attracted more and more attention in the treatment of end-stage liver disease. The investigators therefore conduct a randomised controlled trial to investigate the efficacy and safety of human umbilical cord tissue mesenchymal stem cells for the treatment of end-stage liver disease.
The 2 groups in the trial
- low-dose stem cell group (1×10^6cells/kg per infusion)Treatment being tested
Peripheral intravenous infusion of low-dose stem cells
Treatment: umbilical cord-mesenchymal stem cells
- medium-high-dose stem cell group (3×10^6cells/kg per infusion)Treatment being tested
Peripheral intravenous infusion of medium-high-dose stem cells
Treatment: umbilical cord-mesenchymal stem cells
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With End-stage Liver Diseases
- Record updated
- 3 April 2026